Bristol Myers Squibb (CELG-RI) EPS (Diluted) (QoQ) (2009 - 2026)

Bristol Myers Squibb (CELG-RI) EPS (Diluted) (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 145.72%
Dec 31, 2025 -50.52%
Sep 30, 2025 67.09%
Jun 30, 2025 -46.62%
Mar 31, 2025 3,118.83%
Dec 31, 2024 -93.42%
Sep 30, 2024 -29.09%
Jun 30, 2024 113.65%
Mar 31, 2024 -816.56%
Dec 31, 2023 -12.33%
Sep 30, 2023 -5.17%
Jun 30, 2023 -7.90%
Mar 31, 2023 13.70%
Dec 31, 2022 26.05%
Sep 30, 2022 12.58%
Jun 30, 2022 12.16%
Mar 31, 2022 -43.89%
Dec 31, 2021 60.02%
Sep 30, 2021 49.44%
Jun 30, 2021 -48.97%